Royalty Pharma plc (RPRX)

28.28 -0.21 (-0.74%) 收市：04:00PM EDT

Royalty Pharma plc

110 East 59th Street
New York, NY 10022
United States
212 883 0200
https://www.royaltypharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Pablo Gerardo Legorreta	Founder, Chairman of the Board & CEO	無	無	1965
Mr. Terrance P. Coyne	Executive VP & CFO	4.56M	無	無
Mr. George Wingate Lloyd	Executive VP of Investments & Chief Legal Officer	4.56M	無	1960
Mr. Christopher Hite	Vice Chairman & Executive VP	4.56M	無	1968
Dr. Marshall Jonathan Urist M.D., Ph.D.	Executive Vice President of Research & Investments	4.56M	無	1976
Mr. Arthur Richard McGivern J.D.	Executive Vice President of Investments & General Counsel	無	無	無
Mr. Ashwin Pai M.D.	Executive Vice President of Investments	無	無	無
Ms. Kristin Stafford	Senior VP & Chief Accounting Officer	無	無	1982
Mr. Eric Cornelius Schneider	Senior VP & Chief Technology Officer	無	無	無
Dr. James Folmar Reddoch Ph.D.	Executive VP of Investments & Chief Scientific Officer	3.4M	無	1970

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

公司管治

截至 2024年5月1日 止，Royalty Pharma plc 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：6；董事會：5；股東權利：6；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。